论文部分内容阅读
目的 评价化疗前后血清神经元特异性烯醇化酶 (NSE)检测在非手术治疗小细胞肺癌(SCLC)患者中的预后价值。方法 收集 1997年 6月～ 2 0 0 0年 12月上海市肺科医院内科收治 144例SCLC患者 ,均于化疗前 (D1)和化疗后 2 1d(D2 1)检测NSE水平 ,进行预后单因素和多因素分析。结果144例患者中D1 NSE阳性 98例 ,占 6 8 1% ;阴性 46例 ,占 31 9%。D2 1 NSE阳性 5 7例 ,占 39 6 % ;阴性 87例 ,占 6 0 4% ;单因素分析D1 NSE和D2 1 NSE均是提示预后有价值的指标 ;但COX多因素分析时 ,只有D2 1 NSE是提示预后的独立指标。结论 D2 1 NSE是提示小细胞肺癌预后的独立指标 ,在临床上有较重要的应用价值
Objective To evaluate the prognostic value of serum neuron specific enolase (NSE) before and after chemotherapy in patients with non-surgical treatment of small cell lung cancer (SCLC). Methods From June 1997 to December 2000, 144 patients with SCLC admitted to Shanghai Pulmonary Hospital received NSE before chemotherapy (D1) and 21 days after chemotherapy (D2 1). And multi-factor analysis. Results Of the 144 patients, 98 were positive for D1 NSE, accounting for 68.1%; 46 were negative, accounting for 31.9%. D2 1 NSE positive 57 cases, accounting for 39.6%; negative 87 cases, accounting for 60% 4%; univariate analysis of D1 NSE and D2 1 NSE are prognostic indicators; but COX multivariate analysis, only D2 1 NSE is an independent indicator of prognosis. Conclusions D2 1 NSE is an independent indicator of the prognosis of small cell lung cancer and has clinically important application value.